Gene editing moves from labs to prescriptions. Longevity and cure focus.
$95B
TAM
22%
CAGR
The second wave of CRISPR technology is transitioning from laboratory research to approved therapies. New editing techniques offer greater precision with fewer off-target effects, opening doors to treatments for previously incurable genetic diseases.